A pan-cancer analysis of the clinical and genetic portraits of somatostatin receptor expressing tumor as a potential target of peptide receptor imaging and therapy
Abstract Purpose Although somatostatin receptor (SST) is a promising theranostic target and is widely expressed in tumors of various organs, the indication for therapies targeting SST is limited to typical gastroenteropancreatic neuroendocrine tumors (NETs). Thus, broadening the scope of the current...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2020-04-01
|
| Series: | EJNMMI Research |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s13550-020-00632-2 |
| _version_ | 1819046716480946176 |
|---|---|
| author | Hyunjong Lee Minseok Suh Hongyoon Choi Seunggyun Ha Jin Chul Paeng Gi Jeong Cheon Keon Wook Kang Dong Soo Lee |
| author_facet | Hyunjong Lee Minseok Suh Hongyoon Choi Seunggyun Ha Jin Chul Paeng Gi Jeong Cheon Keon Wook Kang Dong Soo Lee |
| author_sort | Hyunjong Lee |
| collection | DOAJ |
| description | Abstract Purpose Although somatostatin receptor (SST) is a promising theranostic target and is widely expressed in tumors of various organs, the indication for therapies targeting SST is limited to typical gastroenteropancreatic neuroendocrine tumors (NETs). Thus, broadening the scope of the current clinical application of peptide receptor radiotherapy (PRRT) can be supported by a better understanding of the landscape of SST-expressing tumors. Methods SST expression levels were assessed in data from The Cancer Genome Atlas across 10,701 subjects representing 32 cancer types. As the major target of PRRT is SST subtype 2 (SST2), correlation analyses between the pan-cancer profiles, including clinical and genetic features, and SST2 level were conducted. The median SST2 expression level of pheochromocytoma and paraganglioma (PCPG) samples was used as the threshold to define “high-SST2 tumors.” The prognostic value of SST2 in each cancer subtype was evaluated by using Cox proportional regression analysis. Results We constructed a resource of SST expression patterns associated with clinicopathologic features and genomic alterations. It provides an interactive tool to analyze SST expression patterns in various cancer types. As a result, eight of the 31 cancer subtypes other than PCPG had more than 5% of tumors with high-SST2 expression. Low-grade glioma (LGG) showed the highest proportion of high-SST2 tumors, followed by breast invasive carcinoma (BRCA). LGG showed different SST2 levels according to tumor grade and histology. IDH1 mutation was significantly associated with high-SST2 status. In BRCA, the SST2 level was different according to the hormone receptor status. High-SST2 status was significantly associated with good prognosis in LGG patients. High-SST2 status showed a trend for association with poor prognosis in triple-negative breast cancer subjects. Conclusion A broad range of SST2 expression was observed across diverse cancer subtypes. The SST2 expression level showed a significant association with genomic and clinical aspects across cancers, especially in LGG and BRCA. These findings extend our knowledge base to diversify the indications for PRRT as well as SST imaging. |
| first_indexed | 2024-12-21T10:48:53Z |
| format | Article |
| id | doaj.art-eed68b084f6d4878b305dbde1e9cd7fe |
| institution | Directory Open Access Journal |
| issn | 2191-219X |
| language | English |
| last_indexed | 2024-12-21T10:48:53Z |
| publishDate | 2020-04-01 |
| publisher | SpringerOpen |
| record_format | Article |
| series | EJNMMI Research |
| spelling | doaj.art-eed68b084f6d4878b305dbde1e9cd7fe2022-12-21T19:06:44ZengSpringerOpenEJNMMI Research2191-219X2020-04-011011910.1186/s13550-020-00632-2A pan-cancer analysis of the clinical and genetic portraits of somatostatin receptor expressing tumor as a potential target of peptide receptor imaging and therapyHyunjong Lee0Minseok Suh1Hongyoon Choi2Seunggyun Ha3Jin Chul Paeng4Gi Jeong Cheon5Keon Wook Kang6Dong Soo Lee7Department of Nuclear Medicine, Seoul National University Hospital, Seoul National University College of MedicineDepartment of Nuclear Medicine, Seoul National University Hospital, Seoul National University College of MedicineDepartment of Nuclear Medicine, Seoul National University Hospital, Seoul National University College of MedicineDivision of Nuclear Medicine, Department of Radiology, College of Medicine, Seoul St. Mary’s Hospital, The Catholic University of KoreaDepartment of Nuclear Medicine, Seoul National University Hospital, Seoul National University College of MedicineDepartment of Nuclear Medicine, Seoul National University Hospital, Seoul National University College of MedicineDepartment of Nuclear Medicine, Seoul National University Hospital, Seoul National University College of MedicineDepartment of Nuclear Medicine, Seoul National University Hospital, Seoul National University College of MedicineAbstract Purpose Although somatostatin receptor (SST) is a promising theranostic target and is widely expressed in tumors of various organs, the indication for therapies targeting SST is limited to typical gastroenteropancreatic neuroendocrine tumors (NETs). Thus, broadening the scope of the current clinical application of peptide receptor radiotherapy (PRRT) can be supported by a better understanding of the landscape of SST-expressing tumors. Methods SST expression levels were assessed in data from The Cancer Genome Atlas across 10,701 subjects representing 32 cancer types. As the major target of PRRT is SST subtype 2 (SST2), correlation analyses between the pan-cancer profiles, including clinical and genetic features, and SST2 level were conducted. The median SST2 expression level of pheochromocytoma and paraganglioma (PCPG) samples was used as the threshold to define “high-SST2 tumors.” The prognostic value of SST2 in each cancer subtype was evaluated by using Cox proportional regression analysis. Results We constructed a resource of SST expression patterns associated with clinicopathologic features and genomic alterations. It provides an interactive tool to analyze SST expression patterns in various cancer types. As a result, eight of the 31 cancer subtypes other than PCPG had more than 5% of tumors with high-SST2 expression. Low-grade glioma (LGG) showed the highest proportion of high-SST2 tumors, followed by breast invasive carcinoma (BRCA). LGG showed different SST2 levels according to tumor grade and histology. IDH1 mutation was significantly associated with high-SST2 status. In BRCA, the SST2 level was different according to the hormone receptor status. High-SST2 status was significantly associated with good prognosis in LGG patients. High-SST2 status showed a trend for association with poor prognosis in triple-negative breast cancer subjects. Conclusion A broad range of SST2 expression was observed across diverse cancer subtypes. The SST2 expression level showed a significant association with genomic and clinical aspects across cancers, especially in LGG and BRCA. These findings extend our knowledge base to diversify the indications for PRRT as well as SST imaging.http://link.springer.com/article/10.1186/s13550-020-00632-2Somatostatin receptorTCGAPeptide receptor radiotherapyNeuroendocrine tumorPan-cancer profile |
| spellingShingle | Hyunjong Lee Minseok Suh Hongyoon Choi Seunggyun Ha Jin Chul Paeng Gi Jeong Cheon Keon Wook Kang Dong Soo Lee A pan-cancer analysis of the clinical and genetic portraits of somatostatin receptor expressing tumor as a potential target of peptide receptor imaging and therapy EJNMMI Research Somatostatin receptor TCGA Peptide receptor radiotherapy Neuroendocrine tumor Pan-cancer profile |
| title | A pan-cancer analysis of the clinical and genetic portraits of somatostatin receptor expressing tumor as a potential target of peptide receptor imaging and therapy |
| title_full | A pan-cancer analysis of the clinical and genetic portraits of somatostatin receptor expressing tumor as a potential target of peptide receptor imaging and therapy |
| title_fullStr | A pan-cancer analysis of the clinical and genetic portraits of somatostatin receptor expressing tumor as a potential target of peptide receptor imaging and therapy |
| title_full_unstemmed | A pan-cancer analysis of the clinical and genetic portraits of somatostatin receptor expressing tumor as a potential target of peptide receptor imaging and therapy |
| title_short | A pan-cancer analysis of the clinical and genetic portraits of somatostatin receptor expressing tumor as a potential target of peptide receptor imaging and therapy |
| title_sort | pan cancer analysis of the clinical and genetic portraits of somatostatin receptor expressing tumor as a potential target of peptide receptor imaging and therapy |
| topic | Somatostatin receptor TCGA Peptide receptor radiotherapy Neuroendocrine tumor Pan-cancer profile |
| url | http://link.springer.com/article/10.1186/s13550-020-00632-2 |
| work_keys_str_mv | AT hyunjonglee apancanceranalysisoftheclinicalandgeneticportraitsofsomatostatinreceptorexpressingtumorasapotentialtargetofpeptidereceptorimagingandtherapy AT minseoksuh apancanceranalysisoftheclinicalandgeneticportraitsofsomatostatinreceptorexpressingtumorasapotentialtargetofpeptidereceptorimagingandtherapy AT hongyoonchoi apancanceranalysisoftheclinicalandgeneticportraitsofsomatostatinreceptorexpressingtumorasapotentialtargetofpeptidereceptorimagingandtherapy AT seunggyunha apancanceranalysisoftheclinicalandgeneticportraitsofsomatostatinreceptorexpressingtumorasapotentialtargetofpeptidereceptorimagingandtherapy AT jinchulpaeng apancanceranalysisoftheclinicalandgeneticportraitsofsomatostatinreceptorexpressingtumorasapotentialtargetofpeptidereceptorimagingandtherapy AT gijeongcheon apancanceranalysisoftheclinicalandgeneticportraitsofsomatostatinreceptorexpressingtumorasapotentialtargetofpeptidereceptorimagingandtherapy AT keonwookkang apancanceranalysisoftheclinicalandgeneticportraitsofsomatostatinreceptorexpressingtumorasapotentialtargetofpeptidereceptorimagingandtherapy AT dongsoolee apancanceranalysisoftheclinicalandgeneticportraitsofsomatostatinreceptorexpressingtumorasapotentialtargetofpeptidereceptorimagingandtherapy AT hyunjonglee pancanceranalysisoftheclinicalandgeneticportraitsofsomatostatinreceptorexpressingtumorasapotentialtargetofpeptidereceptorimagingandtherapy AT minseoksuh pancanceranalysisoftheclinicalandgeneticportraitsofsomatostatinreceptorexpressingtumorasapotentialtargetofpeptidereceptorimagingandtherapy AT hongyoonchoi pancanceranalysisoftheclinicalandgeneticportraitsofsomatostatinreceptorexpressingtumorasapotentialtargetofpeptidereceptorimagingandtherapy AT seunggyunha pancanceranalysisoftheclinicalandgeneticportraitsofsomatostatinreceptorexpressingtumorasapotentialtargetofpeptidereceptorimagingandtherapy AT jinchulpaeng pancanceranalysisoftheclinicalandgeneticportraitsofsomatostatinreceptorexpressingtumorasapotentialtargetofpeptidereceptorimagingandtherapy AT gijeongcheon pancanceranalysisoftheclinicalandgeneticportraitsofsomatostatinreceptorexpressingtumorasapotentialtargetofpeptidereceptorimagingandtherapy AT keonwookkang pancanceranalysisoftheclinicalandgeneticportraitsofsomatostatinreceptorexpressingtumorasapotentialtargetofpeptidereceptorimagingandtherapy AT dongsoolee pancanceranalysisoftheclinicalandgeneticportraitsofsomatostatinreceptorexpressingtumorasapotentialtargetofpeptidereceptorimagingandtherapy |